Results 71 to 80 of about 159,104 (312)

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Indirect induction of radiation lymphomas in mice. Evidence for a novel, transmissible leukemogen. [PDF]

, 1987
The transmission of a lymphomagenic agent(s) from the bone marrow of irradiated mice to thymic target cells has been demonstrated by: (a) the induction of T cell lymphomas in nonirradiated thymic grafts implanted in irradiated, Thy-l-congenic mice, (b ...
Hansteen, GA, Lieberman, M, McCune, JM, Scott, ML, Weissman, IL, White, JH   +5 more
core  

A Case of Lymphocytic Leukemia in a Bearded Dragon (Pogona vitticeps) and a Review of Literature

Acta Veterinaria, 2019
The present paper reports the case of a 3 years old, female Bearded Dragon (Pogona vitticeps) presenting lethargy, anorexia, weight loss, and anemia and marked leukocytosis at CBC.
Gavazza Alessandra, Galosi Livio, Croce Veronica, Croce Amerio, Genovese Carla, Romano Paolo, Cerquetella Matteo, Rossi Giacomo   +7 more
doaj   +1 more source

A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia

Haematologica, 2009
Background Among patients with B-cell chronic lymphoid leukemia, those with 13q14 deletion have a favorable outcome. However, whether the percentage of cells with 13q- influences the prognosis or the biological characteristics of this disease is unknown.
José Ángel Hernández, Ana Eugenia Rodríguez, Marcos González, Rocío Benito, Celia Fontanillo, Virgilio Sandoval, Mercedes Romero, Guillermo Martín-Núñez, Alfonso García de Coca, Rosa Fisac, Josefina Galende, Isabel Recio, Francisco Ortuño, Juan Luis García, Javier de las Rivas, Norma Carmen Gutiérrez, Jesús F. San Miguel, Jesús María Hernández   +17 more
doaj   +1 more source

TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2

Molecular Cancer, 2023
The reintegration of excised signal joints resulting from human V(D)J recombination was described as a potent source of genomic instability in human lymphoid cancers.
Estelle Balducci, Thomas Steimlé, Charlotte Smith, Patrick Villarese, Mélanie Feroul, Dominique Payet-Bornet, Sophie Kaltenbach, Lucile Couronné, Ludovic Lhermitte, Aurore Touzart, Marie-Emilie Dourthe, Mathieu Simonin, André Baruchel, Hervé Dombret, Norbert Ifrah, Nicolas Boissel, Bertrand Nadel, Elizabeth Macintyre, Agata Cieslak, Vahid Asnafi   +19 more
doaj   +1 more source

Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration

Advanced Science, EarlyView.
Bone regeneration by mesenchymal stem cells is strongly influenced by immune signals. This study shows that priming stem cells with regulatory immune cells or an inflammation‐resolving lipid molecule enhances bone formation through distinct immune pathways.
Salwa Suliman, Carla Alvarez Rivas, Aashish Srivastava, Nora Marek, Kamal Mustafa, Alpdogan Kantarci   +5 more
wiley   +1 more source

Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells [PDF]

, 2013
Purpose: Chronic lymphocytic leukemia (CLL) is currently incurable with standard chemotherapeutic agents, highlighting the need for novel therapies. Overcoming proliferative and cytoprotective signals generated within the microenvironment of lymphoid ...
Alison M. McCaig, Alison M. Michie, Byrd, Christian Berthou, Emilie Durieu, Emilio Cosimo, Helen Wheadon, Hervé Galons, Karine Le Ster, Kitada, Laurent Meijer, Luke J.M. Carter-Brzezinski, Michael T. Leach, Nassima Oumata, Pepper   +14 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia [PDF]

, 2000
At diagnosis, clonal gene rearrangement probes {[}retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3 ...
Braun, S., Duell, T., Gerhartz, Helmut Heinrich, Mittermueller, J., Schmetzer, Helga Maria, Wiesner, D.   +5 more
core   +1 more source

Atypical lymphoid leukemia in ataxia telangiectasia [PDF]

Blood, 1978
We observed two sisters with ataxia telangiectasia, one of whom developed an atypical subacute lymphocytic leukemia characterized by atypical lymphocytes and absence of palpable lymphadenopathy or hepatosplenomegaly. The lack of organomegaly in this patient may have been due to the underlying ataxia telangiectasia, which was associated with lymphoid ...
R, Levitt, R V, Pierre, W L, White, R G, Siekert   +3 more
openaire   +3 more sources